Sorrento to apply antibody library technology for rIVIG production
Sorrento Therapeutics (STI) has acquired global rights to produce recombinant Intravenous immunoglobulins (rIVIG) leveraging STI's G-MAB antibody library technology.
Original Article: Sorrento to apply antibody library technology for rIVIG production
NEXT ARTICLE